Format

Send to

Choose Destination
Cancer Cell. 2013 Feb 11;23(2):238-48. doi: 10.1016/j.ccr.2013.01.007.

EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.

Author information

1
Brain Cancer Research Unit and Leukaemia Foundation Research Unit, Queensland Institute of Medical Research, Brisbane 4006, Australia. bryan.day@qimr.edu.au

Abstract

Significant endeavor has been applied to identify functional therapeutic targets in glioblastoma (GBM) to halt the growth of this aggressive cancer. We show that the receptor tyrosine kinase EphA3 is frequently overexpressed in GBM and, in particular, in the most aggressive mesenchymal subtype. Importantly, EphA3 is highly expressed on the tumor-initiating cell population in glioma and appears critically involved in maintaining tumor cells in a less differentiated state by modulating mitogen-activated protein kinase signaling. EphA3 knockdown or depletion of EphA3-positive tumor cells reduced tumorigenic potential to a degree comparable to treatment with a therapeutic radiolabelled EphA3-specific monoclonal antibody. These results identify EphA3 as a functional, targetable receptor in GBM.

PMID:
23410976
DOI:
10.1016/j.ccr.2013.01.007
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center